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Summary
A population-based study of hemophilia B mutations
was conducted in the United Kingdom in order to con-
struct a national confidential database of mutations and
pedigrees to be used for the provision of carrier and
prenatal diagnoses based on mutation detection. This
allowed the direct estimate of overall (m), male (v), and
female (u) mutation rates for hemophilia B. The values
obtained per gamete per generation and the 95% con-
fidence intervals are (6.29–9.12 ;56m = 7.73 ) # 10 v =
(14.5–22.9 ; and (1.44–3.165618.8 ) # 10 u = 2.18 ) #
. The ratio of male-to-female mutation rates is 8.64,5610
with a 95% confidence interval of 5.46–14.5. The higher
male rate was not caused by a much higher rate of tran-
sition at CpG sites in the male. Attempts to detect evi-
dence of gonadal mosaicism for hemophilia B mutation
in suitable families did not detect any instances of ovar-
ian mosaicism in any of 47 available opportunities. This
suggests that the risk of a noncarrier mother manifesting
as a gonadal mosaic by transmitting the mutation to a
second child should be !0.062.
Introduction
The X-linked recessive disease known as hemophilia B
(MIM 30690) or coagulant factor IX deficiency (Gian-
nelli and Green 1996) offers an opportunity to gain im-
portant insights into human gene mutation. The clear-
cut expression of each hemophilia B gene in the male,
the rapid renewal of these genes in the population, and
the near-normal life span of even severely affected males
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in current populations with good medical care all con-
tribute to the value of this disease for the investigation
of the rates of germline mutations.
The factor IX gene is 33.5 kb in length and comprises
8 exons encoding a polypeptide of 454 residues that is
produced mainly in the liver and is released into the
circulatory system after cleavage of a prepropeptide of
39 amino acids (Anson et al. 1984; Yoshitake et al.
1985).
In countries with long-established national health
services, such as the United Kingdom and Sweden, vir-
tually full ascertainment of affected individuals is
achieved, since every patient is registered on a national
basis at specialist centers responsible for a nationally
integrated system of care. This situation, rare in human
genetics, greatly facilitates investigations. Thus, we be-
gan our population studies on hemophilia B in Sweden
and continued in the United Kingdom (Green et al. 1991;
Saad et al. 1994). In the latter country, we have created
a confidential database of hemophilia B mutations and
pedigrees to optimize the genetic service given nationally
to families affected by hemophilia B (Saad et al. 1994;
P. M. Green, S. Saad, G. Rowley, F. Giannelli, unpub-
lished observations). We now report an analysis of mu-
tation rates in the factor IX gene and discuss its relevance
to mutations in the human genome.
Material and Methods
Samples
Blood samples were requested from hemophilia cen-
ters in the United Kingdom, from U.K.-resident hemo-
philia B patients and relatives. Ten milliliters of blood
collected in EDTA either was sent directly to Guy’s Hos-
pital or was frozen and extracted later.
DNA Preparation, Amplification, and Mutation
Analysis
DNA was extracted from peripheral blood cells by
standard procedures (Miller et al. 1988). Factor IX ex-
ons were amplified by established protocols using prim-
ers flanking each exon, as described elsewhere (Green et
al. 1989). Radioactive chemical mismatch cleavage was
performed as described by Montandon et al. (1989).
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Fluorescent solid-phase chemical cleavage of mismatch
was performed with internal fluorescent labeling (fluo-
rescent dUTPs) and biotinylated primers (Rowley et al.
1995). Both the above methods detect and locate any
mismatches between the test DNA and control, allowing
sequencing to be directed to one of two positions within
the PCR product. Direct DNA sequencing was carried
out as described elsewhere (Green et al. 1989; Winship
1989) to identify the mutation. Mothers and grand-
mothers of isolated patients were screened by sequencing
the relevant exon for the mutation found in the proband.
Carriers of new mutations were screened by both mis-
match analysis and sequencing. Origin of mutation in
one of the grandparents was established by analysis of
intragenic polymorphisms: BamHI,DdeI, TaqI,MnlI (as
described in Green et al. 1992), and HhaI (Winship et
al. 1989).
Identification of Independent Mutational Events
Patients having the same mutation were subjected to
intragenic haplotype analysis for the most frequent and
informative markers (Green et al. 1992). This was gen-
erally performed on DdeI, TaqI, MnlI, and HhaI (see
above). In families with no extensive history of hemo-
philia, evidence for independence was also sought by
determining the origin of the mutation, because changes
occurring in recent generations of nonrelated families
are independent.
Statistical Analysis
The rationale for the estimation of mutation rates
from population data is explained in the Results section.
The confidence intervals for the mutation rates were cal-
culated exactly, where possible (for u, v/u from the num-
ber of grandpaternal and grandmaternal mutations), and
by simulation otherwise, with the assumption of a bi-
nomial distribution for the number of carriers identified.
We assumed that the only source of variation was from
the proportion of mutation carriers identified. The num-
bers of families of the specific structure and with infor-
mation available were assumed to be constants.
Results
Population Analyzed
The United Kingdom’s hemophilia B register lists
1,109 patients served by 95 hemophilia centers, which
are subdivided into 26 “comprehensive care hemophilia
centers” and 69 smaller hemophilia centers. Patients
were referred to us from all (except two) comprehensive
care centers and frommost minor centers. Since the latter
share their patients with the comprehensive care centers,
minor centers that have not contributed directly may
have done so indirectly through their regional compre-
hensive care centers, so the number of noncollaborating
minor centers is difficult to assess. We have analyzed
1,111 samples, comprising 540 patients and 571 rela-
tives. These represent 424 independent families affected
by hemophilia B. Since the national register does not
contain data on family relationships, the total number
of hemophilia B families in the United Kingdom is not
known. However, from the pedigrees of the patients re-
ferred to us, we can arrive at the number of patients
represented by the families that we have analyzed. This
is 800 patients, 72% of the total, but of course this
number is only as precise as the pedigree data allow. The
fraction of patients missing is mainly accounted for by
centers that elected not to collaborate. A small deficit of
mild cases is, however, likely, since these patients have
infrequent interaction with centers that act as referral
points. To counteract this expected trend, we have spe-
cifically asked centers to refer mild patients, and their
positive response is demonstrated by the referral, among
other patients, of eight individuals with no family history
of hemophilia B and with a single, low factor IX assay
result that could not be confirmed by subsequent tests.
These patients are unresolved diagnostic puzzles, since
none showed mutations of the FIX gene, and they are
therefore excluded from this study.
Mutation Analysis
The hemophilia B mutation was sought in each of the
424 independent families by examination of the factor
IX gene of an index person. This, in 403 families, was
an affected male; in 12, an obligatory carrier; and, in 9,
a potential carrier. A mutation was found in 398 of the
403 index patients, in 11 of the 12 obligatory hetero-
zygotes, and in 3 of the 9 potential carriers. Of the 412
mutations characterized, 167 were unique, whereas 50
were observed more than once and account for 245 fam-
ilies. Of these families, 135 show mutations that must
be of independent origin, because these mutations occur
in factor IX genes with different arrangements of poly-
morphic markers or because they have occurred so re-
cently that they cannot be shared by other families with
an identical sequence change. The remaining 110 fam-
ilies show repeats of some of the above mutations. In
19 families, the identical mutation is thought to derive
from a common ancestor, as the result of a founder effect
that so far appears to be limited to the United Kingdom,
whereas in the others, which show repeats of 29 different
mutations, positive evidence of independent origin can-
not be obtained. The types of mutations observed and
their frequency are shown in table 1.
Family Studies
Samples from family members were sought from every
kinship that could provide information on mutation
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Table 1
Types of Hemophilia B Mutations Observed in the United Kingdom
LOCATION
NO. OF MUTATIONS IN CATEGORY
Promoter Missense Nonsense
Splicing
Defects
Transitions
Transversions Frameshifts
In-Frame
Deletions/
Insertions
Gross
Deletions TotalCpG Other
In whole gene:
Independent origin 9 187 39 38 17 7 5 302
Total 13 262 48 58 17 7 7 412
In coding sequence:
Independent origin 76 80 70 17 7 5 255
Total 143 95 72 17 7 7 341
rates or occurrence of gonadal mosaicism—that is, the
families of sporadic patients and the families with a sin-
gle affected sibship. Every request to the hemophilia cen-
ters was accompanied by the appropriate specific mo-
tivation and the recommendation to inform us of any
inability to provide the requested specimens. Whenever
this information was not provided, the sample was re-
quested three times before it was concluded that it was
unobtainable.
Of the 211 sporadic patients, 79 had only the mother
available for study, and 31 had both the mother and
grandmother available. In 10 of the latter three-gener-
ation families, the grandfather was also available.
Twenty-five nonsporadic families appeared to have a sin-
gle affected sibship. In five of these families both the
mother and the maternal grandmother were available
for study; in one the grandfather was also available.
Finally, in families where the patient’s mother was the
origin of the mutation, samples were requested from the
patient’s sisters, and, when one of the grandparents was
the origin of mutation, samples were requested from the
patient’s maternal aunts, because carrier status in such
sisters or aunts would reveal gonadal mosaicism.
Direct Estimate of the Overall and Sex-Specific
Hemophilia B Mutation Rates
Since our studies are clearly and explicitly population
based, we can estimate mutation rates directly by ref-
erence to demographic statistics from the United King-
dom for the past 75 years. These should adequately
cover our population of hemophilia B patients. Statis-
tical data on the hemophilia patients registered in the
United Kingdom were published by Rizza and Spooner
in 1983. These authors calculate a median life expec-
tancy of 69.1 years for severely affected hemophiliacs
and 72.8 years for normal males. Since our population
includes not only severe but also moderate and mild
cases that represent 64% of the whole patient popula-
tion, it is felt that their median life expectancy should
not differ from that of normal males sufficiently to re-
quire specific consideration.
As mentioned previously, the families referred to us
account for 72% of the current population affected by
hemophilia B. However, in 12 families a mutation could
not be found, and for 17 the pedigree was not supplied.
Therefore, the families with both mutation and pedigree
information represent 67.2% of the total population of
the United Kingdom. The bulk of our data was obtained
by 1995, and at that time the population of the United
Kingdom comprised 28.727 million males and 29.878
million females (Office for National Statistics 1997b).
To estimate the mutation rates, it is necessary to de-
termine how many patients and how many patients’
mothers are new mutants. Clearly (barring gonadal mo-
saicism), all patients who are new mutants must be in
the sporadic families, and they are considered to be the
result of mutation in their mother’s germline. We have
211 such families, and in 110 of these the patient’s
mother was available for carrier tests. Of the testable
mothers, 88 (80%) were found to be carriers and 22
were homozygous normal. Thus, extrapolating from this
datum, we find that is the estimated0.2# 211 = 42.2
number of new mutant males in the sample of the United
Kingdom’s hemophilia B population that we have ex-
amined. Since this represents 0.672 of the whole pop-
ulation, the female mutation rate is estimated by u =
(95% con-642.2/(0.672# 28,727,000) = 2.186# 10
fidence interval = 1.44–3.16).
The patients’ mothers who are new mutants must be
found both in the sporadic families mentioned above
and in those which appear to contain a single affected
sibship. In 101 of the sporadic families, the mother was
not available, but, on the basis of the proportions of
carrier and noncarrier mothers found in the 110 infor-
mative families, it can be estimated that 101 # 88
of the missing mothers should be carriers,110 = 80.8
giving a total of 168.8 carrier mothers. Our population
also contains 25 nonsporadic families in which a single
sibship appears to be affected. The patients’ mothers in
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Table 2
Distribution of Hemophilia B Mutations According to Type and Sex of Origin
SOURCES OF DATA AND SEX OF ORIGIN
NO. OF MUTATIONS
Transitions
Transversions
Small
Deletions/
Insertions TotalCpG Non-CpG
Current study:
Known 12 14 12 4 42
Unknown 68 91 68 28 255
Male 2 5 6 3 16
Female 10 9 6 1 26
Montandon et al. (1992), Kling et al. (1992):
Male 3 2 1 0 6
Female 1 0 1 0 2
Ketterling et al. (1993):
Male 3 4 4 1 12
Female 1 3 6 5 15
these sibships should all be carriers, unless they are go-
nadal mosaics. In total, therefore, our population has
193.8 carrier mothers who should comprise all carriers
of a new mutation that was transmitted to at least one
son.
To define the number of these carriers that have a new
mutation, it is necessary to test the patients’ maternal
grandparents. This was possible in 35 families (31 spo-
radic and 4 with a single sibship affected), and in 27 of
these families the mother was a new mutant. Of these
mothers, 24 belonged to sporadic families and 3 to fam-
ilies with a single affected sibship. Extrapolating from
these data, we find that the estimated number of mothers
who are new mutants in the hemophilia B population
considered in our study is and193.8# 27 35 = 149.5
that the estimated number in the whole population is
.149.5 0.672 = 222.5
However, the general population of the United King-
dom must also comprise carriers of new hemophilia B
mutations who have gone unnoticed because they have
not borne an affected son. The number of these carriers
is determined by the probability that a carrier has of
bearing an affected son. This can be estimated by refer-
ring to demographic data on the population of the
United Kingdom. Four sets of data are required: (1) the
average number of liveborn for mothers of age 45
years who can be expected to have completed their fam-
ilies, (2) the average number of liveborn children for the
cohorts of younger women, (3) the proportion of women
of different ages in the population, and (4) the sex ratio
of liveborn children. Since most of our data come from
England and Wales, we have used the figures on family
size for England and Wales, available annually since
1920, and have used the sex ratio of liveborn children
observed in 1995 (Office for National Statistics 1997a).
This indicates that each woman should have produced,
on average, over all age groups, 0.70864 sons. Hence,
a carrier has a chance of pro-0.5# 0.70864 = 0.35432
ducing an affected son, and the estimated frequency
of carriers of a new hemophilia B mutation in the
population of the United Kingdom is the estimated
total number of new carriers in the population:
.6222.5/(0.35432# 29,878,000) = 21.02# 10
Since the new mutation may have arisen in either of
the carrier’s parents, 21.02 # 106 estimates the sum of
the male and female mutation rates, v  u. Since u
was previously estimated, 6v = (21.02 2.18)# 10 =
. It follows that the overall mutation rate618.84# 10
(95% confidence interval6m = (v 2u)/3 = 7.733# 10
6.29–9.12). The rate of male-to-female mutation is
(95% confidence intervals for v and u arev/u = 8.64
14.5–22.9 and 1.44–3.16, respectively, and that for v/u
is 5.46–14.5).
An independent estimate of the ratio of sex-specific
mutation rates (v/u) is the ratio of mothers with new
mutations that originated in grandfathers versus those
with mutations that originated in grandmothers. In our
study, 20 informative families are available: 16 of these
showed mutations of grandpaternal origin, and 4
showed mutations of grandmaternal origin. This gives
(95% confidence interval 1.258–14.13).v/u = 4
If the sex-specific mutation rates differ according to
mutation type, this should be reflected in the distribution
of types among mutations originating in males and fe-
males (table 2). The 42 mutations of clearly defined or-
igin therefore were divided into small deletions and/or
insertions, transitions at CpG sites, transitions not at
CpG sites, and transversions, and the distribution of
each one of these classes versus all the others among
mutations of male or female origin was examined.
Fisher’s exact test did not reveal a statistically significant
difference either when the above data from the United
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Kingdom were tested or when our data from the United
Kingdom and from Sweden (Kling et al. 1992; Mon-
tandon et al. 1992) were added to those of Ketterling
et al. (1993). Since the male origin of a hemophilia B
mutation can be established only in three-generation
families, which are more difficult to obtain than two-
generation families, types of mutations predominantly
arising in the male should be underrepresented in the
group of mutations of known origin, in comparisonwith
the group with undefined origins. However, our data
again show no significant difference in the frequency of
CpG mutations in the above groups.
Data on Gonadal and Somatic Mosaicism
In hemophilia B, the families that can provide infor-
mation on gonadal mosaicism are those with a single
affected sibship containing at least two patients or a
patient and a carrier, those with sibships of sporadic
patients born to noncarrier mothers, and those with sib-
ships of patients’ mothers who carry new mutations. We
tried, therefore, to gather information on these families.
The first of the above types of family can be born either
to a mother who is a demonstrable carrier or to one
with normal somatic cells but mosaic ovaries. In the
second type of family, the patient’s sisters could be car-
riers if the mother were a gonadal mosaic, whereas, in
the third type of family, the patients’ maternal aunts
could be carriers if either grandparent were a gonadal
mosaic, and patients’ uncles could be affected if the
grandmother were a gonadal mosaic.
We elected to disregard the families with a single af-
fected sibship containing more than two mutation-car-
rying individuals, but 49 families with two sibs carrying
mutations remained; in 38 of these families, the mother
was available for study. All of these mothers were found
to be carriers. Twelve sibships born to noncarrier moth-
ers provided a total of 17 informative patient’s sibs, and
they were all mutation free. In addition, the eight sisters
of carriers whose mutation was of paternal origin were
mutation free, and so were five brothers and three sisters
of patients’ mothers whose mutation had arisen in one
of her parents. Thus, in none of the opportunities avail-
able to us was gonadal mosaicism observed. In partic-
ular, we had 47 opportunities to detect ovarian mosai-
cism (i.e., ), without ever38 17/2 8/[2# 8.64] = 47
succeeding. This suggests that a noncarrier mother
should have a risk !6.2% of manifesting gonadal mo-
saicism by transmission of the mutation to a second
child, since 0.062 is the 95% upper exact confidence
limit according to the binomial distribution.
In the course of our mutation studies, we also had a
chance of detecting somatic mosaicism, because our mu-
tation-screening procedure detects mutant DNA even
when it represents merely 10% of the total (Verpy et
al. 1994; A. J. Montandon, personal communication),
whereas the sequencing subsequently applied to char-
acterize the mutation detects mutant DNA only when it
represents ≥30% of the total. Discrepancies between the
results of screening and sequencing were not found in
any one of the 30 individuals who were carrying a new
mutation and who were tested by both these methods.
Discussion
Overall and Sex-Specific Mutation Rates in
Hemophilia B
Perfect data for population genetic studies are very
difficult to obtain. We have mentioned the positive fea-
tures of hemophilia B in this regard, such as the full
registration of patients in the United Kingdom, and their
near-normal median life expectancy, and to this we could
add the ease and specificity of clinical diagnosis (Rizza
1997). Unfortunately, our study did not achieve 100%
referral, but we feel that the sample examined is rep-
resentative of the whole because our deficit is mainly
due to lack of participation by specific centers, rather
than selective referral from centers as a whole. Since its
onset, our work was aimed at studying all families with
the disease in the United Kingdom, and all centers were
aware and were frequently reminded of this fact. Since
large families may be shared by several centers, whereas
sporadic families usually are not, there is the possibility
of overrepresentation of large families; however, this is
tempered by the fact that mutational information is par-
ticularly useful for counseling the families of sporadic
patients, and therefore physicians tend to make an extra
effort to obtain a sample from the isolated patient avail-
able in such families. Failure to recognize multiple re-
porting of the same family is unlikely in our study, be-
cause each pedigree was used to find matches in the
whole pedigree database, and families with identicalmu-
tations were investigated as thoroughly as possible, to
establish whether their mutations were of independent
origin.
In the period between the present and the year of birth
of the oldest hemophilia B patient in the United King-
dom, the mean age at death and the median life expec-
tancy have changed for the 36% of patients who have
severe disease (Rizza and Spooner 1983; Larsson 1985).
This is due to the gradual introduction of more effective
treatment that has led to near-normal life expectancy
since as far back as 20 years ago. Currently infections
resulting from the use of therapeutic blood products are
a cause of concern, but they have so far had modest
effects on the hemophilia B population of the United
Kingdom. The remaining 64%of patients withmoderate
to mild disease have had near-normal life expectancy
even when therapy was less effective than it was 20 years
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ago. It is therefore reasonable to assume that the struc-
tures of the hemophilia B and normal populations in the
United Kingdom are not markedly different.
Our data on hemophilia B derived from a sample that
is very likely to be representative of the whole population
and that is also the largest sample examined so far. These
data therefore provide an excellent opportunity to ob-
tain a direct estimate of mutation rates. This we have
done with the help of appropriate demographic data,
and the following estimates were obtained for the overall
(m), female (u) and male (v) mutation rates, which are,
respectively, (95% confidence interval6m = 7.73# 10
6.29–9.12); (95% confidence interval6u = 2.18# 10
1.44–3.16); and (95% confidence in-6v = 18.82# 10
terval 14.5–22.9). This gives a ratio of male-to-female
mutation rates of 8.64 (95% confidence interval
5.46–14.5), which is compatible with the independent
estimate of the ratio of sex-specific mutation rates ob-
tained by dividing the number of carriers of new mu-
tations whose defective gene is of paternal origin by
those whose hemophilia B gene is of maternal origin
( [95% confidence interval 1.26–14.1]). Further-v/u = 4
more, the first direct estimate of the ratio of sex-specific
mutation rates for hemophilia B obtained on the much
smaller Swedish sample ( ) lies in the confi-v/u ∼ 11
dence interval of the estimate for the United Kingdom
(Montandon et al. 1992).
Ketterling et al. (1993), who also report a high ratio
of male-to-female mutation rates in hemophilia B, have
suggested that this is mainly due to an excess of CpG
transitions in the male gonad.Wewere unable to confirm
this suggestion, since our data do not show any signif-
icant difference when the four mutation types (transi-
tions at CpG sites, transitions at non-CpG sites, trans-
versions, and small deletions/insertions) are compared
according to sex of origin. Furthermore, the combined
data on mutations of known origin from Ketterling et
al. (1993), the Swedish sample that we examined else-
where (Kling et al. 1992; Montandon et al. 1992), and
the present study also show no significant differences
regarding the above four classes of small mutations. Fi-
nally, our accompanying paper (Giannelli et al. 1999 [in
this issue]) shows data, on the divergence of human and
chimpanzee sequences from the Y and X chromosomes,
that are also inconsistent with the contentions of Ket-
terling et al. (1993), because they do not reveal a much
greater proportion of CpG transitions in the Y than in
the X chromosome sequences when these transitions are
considered in relation to the other transitions, as would
be required if the conclusions of Ketterling et al. (1993)
were true.
Ketterling et al. (1993) consider the excess of transi-
tion at CpG sites in the male to be an important argu-
ment in favor of their tenet that the pattern of hemo-
philia B mutations negates a significant role of en-
vironmental factors in germline mutagenesis, because, in
their view, the higher methylation in the male germline
would be the cause of such a high male-to-female ratio.
Furthermore, they also report an excess of transversion
at CpG sites, which they ascribe to the instability of
methylated cytosines (Ketterling et al. 1994). However,
Chen et al. (1998) report that cytosine methylation en-
hances guanine alkylation by mutagens; the latter ob-
servation by Ketterling et al. (1994) thus could also be
construed as evidence of environmental mutagenesis.
Our study, however, does not show an excess of CpG
transversion (see accompanying paper Giannelli et al.
1999 [in this issue]), but data on this type of mutation
are still too scanty to allow us to arrive at reliable
conclusions.
A high male-to-female ratio has been reported for
other diseases with a mutational spectrum similar to that
of hemophilia B. Thus, for example, the study of 126
sporadic families with severe hemophilia A (MIM
30670), by Becker et al. (1996), suggests a ratio of 5–10
for point mutations and a ratio 110 for the inversions
that cause almost half of all severe cases of this X-linked
recessive disease (Lakich et al. 1993; Naylor et al. 1993).
An even higher ratio of male-to-female mutation
rates—52—was claimed by Tuchman et al. (1995) for
the semidominant X-linked disorder ornithine transcar-
bamylase deficiency (MIM 31125). That study, however,
was based on only 43 mutants collected in different
countries.
Gonadal Mosaicism for Hemophilia B Mutations
A question of concern to the genetic counselor is
whether mutations occur in such a way as to lead fre-
quently to gonadal mosaicism and hence to significant
recurrence risk for “noncarrier” parents.Work onDuch-
enne muscular dystrophy (DMD [MIM 31020]) has
highlighted this problem, since noncarrier mothers of
DMD patients were found to have a 20% risk of trans-
mitting the DMD mutation to a second child whenever
they transmitted the haplotype present in their sporadic
affected sons (van Essen et al. 1992). However, most
DMD mutations are gross deletions, and data on DMD
may be irrelevant to diseases with a different mutational
spectrum, such as hemophilia B. Gonadal and somatic
mosaicism have been reported for hemophilia B muta-
tions, but these observations are essentially anecdotal
and are difficult to relate to population risks (Taylor et
al. 1991; Sommer et al. 1995). Furthermore, a variety
of technical and clerical errors may result in apparent
mosaicism and may contribute to positive reports.
Therefore it would be important to obtain broad-based
population data. We have attempted to do so. Our ef-
forts have been rewarded by a moderate number of po-
tentially informative events, and in none of these events
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was mosaicism observed. This seems to suggest that go-
nadal mosaicism for hemophilia B mutations is less com-
mon than in DMD, since the probability of a noncarrier
mother manifesting as an ovarian mosaic should be
!0.062.
In conclusion, using the population data from the
United Kingdom we obtain the best direct estimates so
far of the overall and sex-specific mutation rates for
hemophilia B. Our data clearly contradict the claim that
the higher mutation rate observed in males is essentially
due to transitions at CpG sites and thus change the per-
spective on the causes of the high ratio of sex-specific
mutation rates. Finally, the data collected on gonadal
mosaicism suggest that this phenomenon is not likely to
be a major cause of problems in the genetic service for
hemophilia B.
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